Literature DB >> 18784372

Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator.

Tina Van Den Broeck1, Frederik Stevenaert, Sylvie Taveirne, Veronique Debacker, Christel Vangestel, Bart Vandekerckhove, Tom Taghon, Patrick Matthys, Jean Plum, Werner Held, Mieke Dewerchin, Wayne M Yokoyama, Georges Leclercq.   

Abstract

The Ly49 natural killer (NK)-cell receptor family comprises both activating and inhibitory members, which recognize major histocompatibility complex (MHC) class I or MHC class I-related molecules and are involved in target recognition. As previously shown, the Ly49E receptor fails to bind to a variety of soluble or cell-bound MHC class I molecules, indicating that its ligand is not an MHC class I molecule. Using BWZ.36 reporter cells, we demonstrate triggering of Ly49E by the completely distinct, non-MHC-related protein urokinase plasminogen activator (uPA). uPA is known to be secreted by a variety of cells, including epithelial and hematopoietic cells, and levels are up-regulated during tissue remodeling, infections, and tumorigenesis. Here we show that addition of uPA to Ly49E-positive adult and fetal NK cells inhibits interferon-gamma secretion and reduces their cytotoxic potential, respectively. These uPA-mediated effects are Ly49E-dependent, as they are reversed by addition of anti-Ly49E monoclonal antibody and by down-regulation of Ly49E expression using RNA interference. Our results suggest that uPA, besides its established role in fibrinolysis, tissue remodeling, and tumor metastasis, could be involved in NK cell-mediated immune surveillance and tumor escape.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18784372     DOI: 10.1182/blood-2008-06-164350

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Ly49E separates liver ILC1s into embryo-derived and postnatal subsets with different functions.

Authors:  Yawen Chen; Xianwei Wang; Xiaolei Hao; Bin Li; Wanyin Tao; Shu Zhu; Kun Qu; Haiming Wei; Rui Sun; Hui Peng; Zhigang Tian
Journal:  J Exp Med       Date:  2022-03-29       Impact factor: 14.307

2.  The Ly49E Receptor Inhibits the Immune Control of Acute Trypanosoma cruzi Infection.

Authors:  Jessica Filtjens; Nicolas Coltel; Sabrina Cencig; Sylvie Taveirne; Els Van Ammel; Aline Van Acker; Tessa Kerre; Patrick Matthys; Tom Taghon; Bart Vandekerckhove; Yves Carlier; Carine Truyens; Georges Leclercq
Journal:  Front Immunol       Date:  2016-11-10       Impact factor: 7.561

Review 3.  Natural Killer Cells: Tumor Surveillance and Signaling.

Authors:  Lizeth G Meza Guzman; Narelle Keating; Sandra E Nicholson
Journal:  Cancers (Basel)       Date:  2020-04-11       Impact factor: 6.639

4.  The ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection.

Authors:  Alan Rowe Schenkel; Luke C Kingry; Richard A Slayden
Journal:  Front Immunol       Date:  2013-04-16       Impact factor: 7.561

5.  Contribution of the Ly49E natural killer receptor in the immune response to Plasmodium berghei infection and control of hepatic parasite development.

Authors:  Jessica Filtjens; Lander Foquet; Sylvie Taveirne; Els Van Ammel; Mandy Vanhees; Aline Van Acker; Tessa Kerre; Tom Taghon; Bart Vandekerckhove; Jean Plum; Philippe E Van den Steen; Georges Leclercq
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

6.  Expression of the inhibitory Ly49E receptor is not critically involved in the immune response against cutaneous, pulmonary or liver tumours.

Authors:  Jessica Filtjens; Jiri Keirsse; Els Van Ammel; Sylvie Taveirne; Aline Van Acker; Tessa Kerre; Tom Taghon; Bart Vandekerckhove; Jean Plum; Jo A Van Ginderachter; Georges Leclercq
Journal:  Sci Rep       Date:  2016-07-29       Impact factor: 4.379

7.  Memory formation and long-term maintenance of IL-7Rα+ ILC1s via a lymph node-liver axis.

Authors:  Xianwei Wang; Hui Peng; Jingjing Cong; Xuefu Wang; Zhexiong Lian; Haiming Wei; Rui Sun; Zhigang Tian
Journal:  Nat Commun       Date:  2018-11-19       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.